10-Q: Heron Therapeutics Reports Q3 2024 Results, Revenue Up, Losses Narrow

Heron Therapeutics saw a revenue increase in Q3 2024 compared to Q3 2023, while also reducing its net loss.

Summary

• Heron Therapeutics reported a net product sales increase to $32.8 million for the three months ended September 30, 2024, compared to $31.4 million for the same period in 2023.
• For the nine months ended September 30, 2024, net product sales reached $103.5 million, up from $92.8 million in the same period of 2023.
• The company's net loss for the quarter was $4.8 million, or $0.03 per share, a significant improvement from the $25.0 million loss, or $0.17 per share, in Q3 2023.
• The net loss for the nine months ended September 30, 2024, was $17.2 million, or $0.11 per share, compared to a net loss of $99.8 million, or $0.75 per share, for the same period in 2023.
• As of September 30, 2024, Heron had $70.9 million in cash, cash equivalents, and short-term investments.
• Management believes that the company's current cash position will be sufficient to meet its anticipated cash requirements for at least the next twelve months.

Sentiment

Score: 7

Explanation: The sentiment is positive due to increased revenue, reduced losses, and a sufficient cash position. However, the company faces significant competition and ongoing legal challenges, which temper the overall outlook.

Positives

• The company experienced a notable increase in net product sales for both the quarter and the first nine months of 2024.
• Heron significantly reduced its net loss in Q3 2024 compared to the same period in 2023.
• The company's cash position is considered sufficient to meet its needs for at least the next twelve months.
• The introduction of the VAN for ZYNRELEF is expected to simplify preparation and enhance safe use.
• The partnership with CrossLink is expected to expand the sales network for ZYNRELEF.
• ZYNRELEF will receive separate Medicare reimbursement in hospital outpatient and ambulatory surgical center settings starting in 2025.

Negatives

• Cost of product sales included charges of $0.8 million and $2.4 million relating to reserves and write-offs of inventory for the three and nine months ended September 30, 2024, respectively.
• Other expense, net increased due to higher interest expenses from a working capital facility agreement and write-offs of property and equipment.
• There was a decrease in net product sales for CINVANTI for the three months ended September 30, 2024, as compared to 2023 due to increased gross to net adjustments.
• There was a decrease in net product sales for SUSTOL for the three months ended September 30, 2024, as compared to 2023 due to a decrease in units sold.

Risks

• The company faces intense competition in the postoperative pain management, CINV, and PONV markets.
• There are ongoing legal proceedings related to patent infringement of CINVANTI and APONVIE.
• The company relies on third-party contract manufacturers for its products.
• Unanticipated delays due to manufacturing difficulties or supply constraints could impact the business.
• The company's ability to achieve profitability is uncertain.
• The company may need to obtain additional financing to fund operations or pursue business opportunities.

Future Outlook

Management believes that the company's current cash, cash equivalents, short-term investments and working capital facility will be sufficient to meet its anticipated cash requirements for at least the next twelve months. The company also anticipates the launch of the VAN for ZYNRELEF in Q4 2024 and the expansion of the ZYNRELEF sales network through the CrossLink partnership.

Management Comments

• Management believes that the Company's cash, cash equivalents and short-term investments will be sufficient to meet the Company's anticipated cash requirements for a period of at least one year from the date this Quarterly Report on Form 10-Q is filed with the U.S. Securities and Exchange Commission (SEC).
• Management believes that the company's current cash position will be sufficient to meet its needs for at least the next twelve months.

Industry Context

The report highlights Heron's efforts to compete in the acute care and oncology markets with its portfolio of products. The company is navigating a competitive landscape with established players and generic alternatives. The report also notes the importance of reimbursement pathways, such as Medicare pass-through status, for the success of its products.

Comparison to Industry Standards

• Heron's products, such as ZYNRELEF, compete with established pain management options like Pfizer's MARCAINE and Pacira BioSciences' EXPAREL, as well as generic bupivacaine.
• APONVIE competes with generic ondansetron and aprepitant, as well as Eagle Pharmaceuticals' BARHEMSYS in the PONV prevention market.
• CINVANTI faces competition from Merck's EMEND IV and generic fosaprepitant, as well as other NK1 receptor antagonists.
• SUSTOL competes with other 5-HT3 receptor antagonists like Helsinn's AKYNZEO and Cumberland Pharmaceuticals' SANCUSO, as well as generic ondansetron, granisetron, and palonosetron.
• The company's focus on extended-release formulations, such as ZYNRELEF and SUSTOL, is a differentiator in the market.
• The company's legal battles with generic manufacturers are common in the pharmaceutical industry, as companies seek to protect their intellectual property.

Legal Proceedings

• Heron is involved in patent infringement litigation with Fresenius Kabi, Mylan, and Slayback regarding CINVANTI and APONVIE.
• The company intends to vigorously enforce its intellectual property rights related to these products.

Stakeholder Impact

• Shareholders will be impacted by the company's financial performance and the outcome of ongoing litigation.
• Employees may be affected by the company's restructuring and operational efficiencies.
• Customers (healthcare providers and hospitals) will benefit from the company's products and their reimbursement status.
• Suppliers and creditors will be impacted by the company's financial stability and ability to meet its obligations.

Next Steps

• The company plans to launch the vial access needle (VAN) for ZYNRELEF in the fourth quarter of 2024.
• The company will continue to expand the sales network for ZYNRELEF through its partnership with CrossLink.
• The company will continue to defend its intellectual property rights in ongoing legal proceedings.
• The company will continue to monitor and evaluate the realizable value of its marketable securities.

Key Dates

Keywords

ZYNRELEF, APONVIE, CINVANTI, SUSTOL, postoperative pain, chemotherapy-induced nausea and vomiting, PONV, oncology, pharmaceuticals, biotechnology